Skip to main content
Premium Trial:

Request an Annual Quote

Google Invests Another $2.6M in 23andMe

NEW YORK (GenomeWeb News) – Google has invested $2.6 million in 23andMe through a Series B financing, according to a US Securities and Exchange filing by Google yesterday.

Google has invested around $7 million thus far in the consumer genetics startup. Two years ago, Google invested $3.9 million in 23andMe through a Series A round of financing. It also purchased $500,000 of 23andMe's Series A preferred stock from a private investor in 2007.

Sergey Brin, president of technology and a co-founder of Google is the husband of 23andMe Co-founder Anne Wojcicki. He previously invested around $10 million of his own money in 23andMe's convertible debt financing, which was converted into Series B preferred stock as part of 23andMe's Series B round.

Google noted in the SEC filing that the valuation of the Series B investment was determined by 23andMe and New Enterprise Associates — a venture capital investor in 23andMe — in which Google did not play a role.

23andMe has not yet disclosed how much in total it raised through the Series B round or the names of the other investors in addition to Google and New Enterprise Associates.

Google also disclosed in the filing that it had entered into a lease agreement with 23andMe, but it did not provide further details.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.